Recruitment into studies assessing optimum duration of treatment must continue

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7037.1036b (Published 20 April 1996) Cite this as: BMJ 1996;312:1036
  1. Helena Earl,
  2. Pat Baker,
  3. David Kerr,
  4. Martin Lee,
  5. Richard Gray,
  6. Michael Baum
  1. On behalf of the steering committee of the aTTom study Cochair, aTTom study Senior trial coordinator Professor of oncology CRC Trials Unit, CRC Institute for Cancer Studies, University of Birmingham, Queen Elizabeth Hospital, Birmingham B15 2TT
  2. Cochair, aTTom study City Hospital NHS Trust, Birmingham B18 7QH
  3. Senior research statistician, aTTom study Clinical Trial Service Unit, Radcliffe Infirmary, University of Oxford, Oxford OX2 6HE
  4. Professor of surgery Royal Marsden Hospital, London SW3 6JJ

    EDITOR,—R D Bulbrook's editorial prejudges the issue of the duration of tamoxifen as adjuvant treatment for breast cancer.1 Its conclusions are based on an announcement by the American National Cancer Institute that the national surgical adjuvant breast and bowel project trial B-14, which compared five with up to 10 years of tamoxifen, was to be stopped on the advice of the data monitoring committee. On the basis of unpublished data from just over 1500 randomised patients from this and a Scottish study …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription